Episodes
Wednesday Dec 15, 2021
ATS guidelines in COPD: When is one therapy not enough?
Wednesday Dec 15, 2021
Wednesday Dec 15, 2021
Dr Richard Russell and Professor Michael Dreher present the 2020 American Thoracic Society Guidelines on the management of COPD,1 to which Professor Dreher was a key contributor. Listen as the experts deliberate on the use of dual bronchodilation and inhaled corticosteroids in patients with COPD, as well as reviewing conditional and strong recommendations for treatment, according to the guidelines.1,2 Dr Russell will also discuss the findings of a publication about maintenance inhaler therapy preferences of patients with COPD.3 Finally, Dr Russell will delve into the social media hot topic of air pollution and the effects it can have on patients with COPD.
1 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e69;2 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;3 Tervonen T, et al. Thorax 2020;75:735–743
DisclosuresProfessor Michael DreherProfessor Michael Dreher reports speaker fees from Actelion Pharmaceuticals, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Hamilton, Heinen und Löwenstein, Linde, Novartis, Pfizer, Philips Respironics, ResMed, Roche and Weinmann. He also reports consulting fees from Almirall, Boehringer Ingelheim, Linde, Novartis, Pfizer, Philips Respironics, ResMed and Roche, and research grants from Linde, Philips Respironics and ResMed.
Bios:
Professor Michael DreherProfessor Michael Dreher is the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany). He is Member of the Board of Trustees of the "Deutsche Lungenstiftung“and management board member of several German societies, including the German Airway League. Prof Dreher's research interests focus on the management of chronic obstructive pulmonary disease and other lung diseases, and also include aspects of critical care medicine.
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.
Wednesday Dec 01, 2021
Is two better than one? Early optimisation with dual bronchodilation in COPD
Wednesday Dec 01, 2021
Wednesday Dec 01, 2021
Professor Dave Singh joins Dr Richard Russell to explore the benefits of using dual bronchodilation versus monobronchodilation in patients with COPD.1 They will explain the impact of breathlessness and physical inactivity on patients,2,3 as well as what the clinical guidelines recommend in terms of initial and follow-up treatment for COPD.1,4 A new publication focusing on the long-term effects of pulmonary rehabilitation in elderly patients will be highlighted by Dr Russell,5 followed by a review of the impact of biomass fuel on COPD, a current hot topic on social media.
1 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available here. Last accessed: November 2021;2 Troosters T, et al. Respir Med 2010;104:1005–1011;3 Waschki B, et al. Chest 2011;140:331–342;4 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e59;5 Gephine S, et al. Int J Chron Obstruct Pulmon Dis 2020;15:2505–2514.
DisclosuresDr Richard RussellDr Richard Russell has received speaker fees from AstraZeneca, GlaxoSmithKline, Chiesi and Boehringer Ingelheim. He has also received project grant support from AstraZeneca.
Professor Dave SinghProfessor Dave Singh has received personal fees from Aerogen, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, EpiEndo, Genentech, GlaxoSmithKline, Glenmark, Gossamer Bio, Kinaset, Menarini, Novartis, Pulmatrix, Sanofi, Teva, Theravance and Verona.
Bios:
Dr Richard RussellDr Richard Russell is a Consultant Chest Physician at Lymington New Forest Hospital (UK), as well as a Senior Clinical Researcher at the University of Oxford, and is the founding editor of the International Journal of COPD. He is also the Clinical Lead for Respiratory Medicine, Southeast England, UK, the Director of West Hampshire Integrated Respiratory Service, UK, and an Honorary Senior Lecturer at Imperial College London, UK.
Professor Dave SinghDave Singh is Professor of Clinical Pharmacology & Respiratory Medicine at the University of Manchester and supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). He graduated in medicine from Cambridge University and then specialised in clinical pharmacology and respiratory medicine. His research interest is the development of new drugs for asthma and COPD. He is the Medical Director of the Medicines Evaluation Unit at the University of Manchester, where he has acted as principal investigator in over 300 clinical trials. He is a member of the GOLD Science Committee, and an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society, and has over 350 publications.
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.
Thursday Nov 11, 2021
The use of ICS in COPD: Discussing new European Respiratory Society Guidelines
Thursday Nov 11, 2021
Thursday Nov 11, 2021
In this episode of the Medical Insider COPD podcast, join Dr Richard Russell and Professor James Chalmers as they discuss the implications of the recent European Respiratory Society Guidelines on COPD patient care.1 Listen as the experts debate the use of inhaled corticosteroids and discuss who is most likely to benefit from their withdrawal. 1 Dr Russell also shares highlights from a publication about patients’ healthcare system encounters before they receive a COPD diagnosis.2 Finally, Dr Russell delves into a hot social media topic, looking at the implications that diet and nutrition can have for patients with COPD.
1. Chalmers JD, et al. Eur Respir J 2020;55:2000351;2. Johnson KM, et al. Thorax 2020;75:108–115.
DisclosuresProfessor James Chalmers
Professor James Chalmers has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Insmed, Janssen, Novartis and Zambon
Research grant support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Insmed and Novartis
Dr Richard Russell
Dr Richard Russell has received speaker fees from AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim.
Project grant support from AstraZeneca
Funding statementThis podcast programme was developed by an independent editorial board, funded by Boehringer Ingelheim. Boehringer Ingelheim was given the opportunity to review for medical and scientific accuracy.
This series of podcasts are intended for healthcare professionals only.
The Medical Insider COPD podcast series discusses hot topics in the world of COPD with those who know it best, aiming to spread information, debunk myths and improve the lives of patients. The Editorial Board of the Medical Insider COPD podcast is comprised of Professor James Chalmers, the British Lung Foundation Chair of Respiratory Research at the University of Dundee (UK), Professor Michael Dreher, the Head of the Department of Pneumology and Intensive Care Medicine at the University Hospital Aachen (Germany), and the host and moderator, Dr Richard Russell, a Consultant Chest Physician at Lymington New Forest Hospital (UK), a Senior Clinical Researcher at the University of Oxford (UK) and the founding editor of the International Journal of COPD. These series of podcasts have not been peer-reviewed, but have been vetted by the journal’s Editor-in-Chief.
Copyright © 2021, Boehringer Ingelheim Group of Companies. All rights reserved.